(PHYL) PGIM Active High Yield Bond - Ratings and Ratios
High-Yield Bonds, Below-Investment-Grade Securities, Distressed Debt
Dividends
| Dividend Yield | 7.43% |
| Yield on Cost 5y | 9.30% |
| Yield CAGR 5y | -1.42% |
| Payout Consistency | 95.2% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 3.32% |
| Value at Risk 5%th | 5.47% |
| Relative Tail Risk | 0.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.82 |
| Alpha | 1.98 |
| CAGR/Max DD | 2.00 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.527 |
| Beta | 0.182 |
| Beta Downside | 0.216 |
| Drawdowns 3y | |
|---|---|
| Max DD | 4.52% |
| Mean DD | 0.75% |
| Median DD | 0.40% |
Description: PHYL PGIM Active High Yield Bond October 27, 2025
PHYL seeks to allocate at least 80% of its investable assets to a broadly diversified pool of high-yield, below-investment-grade bonds and comparable securities, including derivatives that mirror the same economic profile. The fund is also permitted to hold distressed instruments-such as securities in bankruptcy or default, or those rated in the lowest rating tiers-provided the Sub-Adviser judges their credit quality to be acceptable.
Key metrics that investors typically monitor for PHYL include a weighted-average yield around 7.5% and an average duration of roughly 5 years, positioning the ETF to benefit from a steepening yield curve while remaining sensitive to credit spreads. The fund’s performance is closely tied to macro-economic drivers such as U.S. corporate debt issuance trends, Federal Reserve policy on interest rates, and the prevailing recession risk premium. Sector exposure is often weighted toward energy, industrials, and consumer discretionary issuers, which together account for over 40% of the portfolio’s holdings.
For a deeper quantitative breakdown of PHYL’s risk-return profile, you might explore ValueRay’s interactive analytics platform.
What is the price of PHYL shares?
Over the past week, the price has changed by -0.08%, over one month by +0.48%, over three months by +0.80% and over the past year by +8.29%.
Is PHYL a buy, sell or hold?
What are the forecasts/targets for the PHYL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 40.2 | 13.4% |
PHYL Fundamental Data Overview December 05, 2025
Beta = 0.67
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 609.6m USD (609.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 609.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 609.6m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.68% (E(609.6m)/V(609.6m) * Re(6.68%) + (debt-free company))
Discount Rate = 6.68% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for PHYL ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle